Sumitomo Mitsui DS Asset Management Company Ltd Sells 4,108 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sumitomo Mitsui DS Asset Management Company Ltd decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,100 shares of the company’s stock after selling 4,108 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in IDEXX Laboratories were worth $8,310,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the 4th quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $459.78 on Friday. The firm has a market cap of $37.65 billion, a PE ratio of 44.34, a P/E/G ratio of 3.64 and a beta of 1.37. The stock has a 50-day moving average price of $427.59 and a 200-day moving average price of $453.67. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.18% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research reports. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $524.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.